中文摘要：

目的探讨不同剂量瑞舒伐他汀对急性冠脉综合征患者血清血管细胞黏附分子-1（VCAM-1）、细胞间黏附分子-1（ICAM-1）和纤溶酶原激活物抑制剂-1（PAI-1）水平的影响。方法将急性冠脉综合征患者256例随机分成A组（瑞舒伐他汀10mg/d,128例）,B组（瑞舒伐他汀20mg/d,128例）,另选50例冠状动脉造影检查证实无冠状动脉狭窄者设为对照组。分别于治疗前及治疗后1周、2周收集血液,采用酶联免疫吸附剂法测定血清VCAM-1、ICAM-1和PAI-1浓度。结果急性冠脉综合征患者血清中VCAM-1、ICAM-1和PAI-1的水平明显高于正常对照组（P〈0.05）;A组、B组在治疗后1周、2周VCAW-1、ICAM-1和PAI-1的水平较治疗前降低（P〈0.05）;B组在治疗后VCAW-1、ICAM-1和PAI-1水平均较A组低（P〈0.05）。结论瑞舒伐他汀可以有效降低ACS患者血清中VCAM-1、ICAM-1和PAI-1的水平,且随着瑞舒伐他汀剂量的增加,其降低ACS患者血清VCAM-1、ICAM-1和PAI-1水平的作用更为显著。

英文摘要：

Objective To explorer the effect of different doses of rosuvastatin on serum concentrations of vascular cell adhesion molecule l (VCAM 1),intercellular adhesion molecule 1(ICAM 1),and plasminogen activator inhibitor 1 (PAI 1)in the pa-tients with acute coronary syndrome (ACS).Methods A total of 236 patients with acute coronary syndrome were randomly divided into A group (128 patients were administrated to rosuvastain 10 mg per day)and B group (128 patients were administrated to rosuv-astain 20 mg per day).Another 50 age matched healthy subjects who were confirmed no coronary artery stenosis by coronary angi-ography were enrolled as control group.Serum samples of the patients in both A and B group were collected in order to detect the level of VCAM 1,ICAM 1,and PAI 1 before the patients accept rosuvastain and 1 and 2 weeks after the treatment.The level of VCAM 1, ICAM 1 ,and PAI 1 were measured by Enzyme Linked Immunosorbent Assay.Results Compared with the control group,the con-centrations of serum VCAM 1,ICAM 1,and PAI 1 were significantly increased in patients with ACS (P<0.05).After 1 and 2 weeks of the treatment,the concentrations of serum VCAM 1,ICAM 1,PAI 1 were decreased both in A and B group (P<0.05). Whereas in the B group,the concentrations of serum VCAM 1 ,ICAM 1 ,and PAI 1 were lower than that in the A group both 1 and 2 weeks after the treatment (P<0.05).Conclusion Significant decreases of VCAM 1,ICAM 1 and PAI 1 in ACS patients were observed at both 1 and 2 weeks after treatment with rosuvastatin,and significantly greater reduction were observed with the in-creasing dose of rosuvastatin.